XML 19 R6.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (UNAUDITED) - USD ($)
shares in Thousands, $ in Millions
Total
Directors
Greif, Inc. Equity
Greif, Inc. Equity
Directors
Common Stock
Common Stock
Directors
Treasury Stock
Treasury Stock
Directors
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Non controlling interests
Beginning balance (in shares) at Sep. 30, 2024         47,181            
Beginning balance at Sep. 30, 2024 $ 2,134.3   $ 2,088.3   $ 229.7   $ (279.0)   $ 2,485.2 $ (347.6) $ 46.0
Beginning balance (in shares) at Sep. 30, 2024             29,661        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 73.1   61.9           61.9   11.2
Other comprehensive income (loss):                      
Foreign currency translation, net of income tax benefit (expense) (33.2)   (32.9)             (32.9) (0.3)
Derivative financial instruments, net of income tax benefit (expense) 30.3   30.3             30.3  
Minimum pension liability adjustment, net of income tax (expense) benefit 2.1   2.1             2.1  
Comprehensive income 72.3   61.4                
Current period mark to redemption value of redeemable noncontrolling interest and other (3.5)   (3.5)           (3.5)    
Net income allocated to redeemable noncontrolling interests (3.9)                   (3.9)
Dividends paid to Greif, Inc. shareholders (62.4)   (62.4)           (62.4)    
Dividends paid to noncontrolling interests and other (11.5)                   (11.5)
Dividends earned on RSU shares (0.1)   (0.1)           (0.1)    
Colleague stock purchase plan (in shares)         45   (45)        
Colleague stock purchase plan 2.7   2.7   $ 2.4   $ 0.3        
Long-term incentive shares issued (in shares)         211   (211)        
Long-term incentive shares issued 8.4   8.4   $ 6.7   $ 1.7        
Share based compensation 2.5   2.5   $ 2.5            
Restricted stock, directors (in shares)           24   (24)      
Restricted stock, directors   $ 1.5   $ 1.5   $ 1.3   $ 0.2      
Ending balance (in shares) at Mar. 31, 2025         47,461            
Ending balance at Mar. 31, 2025 2,140.3   2,098.8   $ 242.6   $ (276.8)   2,481.1 (348.1) 41.5
Ending balance (in shares) at Mar. 31, 2025             29,381        
Beginning balance (in shares) at Dec. 31, 2024         47,181            
Beginning balance at Dec. 31, 2024 2,077.1   2,040.0   $ 231.4   $ (279.0)   2,473.4 (385.8) 37.1
Beginning balance (in shares) at Dec. 31, 2024             29,661        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 46.4   39.9           39.9   6.5
Other comprehensive income (loss):                      
Foreign currency translation, net of income tax benefit (expense) 60.8   60.3             60.3 0.5
Derivative financial instruments, net of income tax benefit (expense) (21.2)   (21.2)             (21.2)  
Minimum pension liability adjustment, net of income tax (expense) benefit (1.4)   (1.4)             (1.4)  
Comprehensive income 84.6   77.6                
Current period mark to redemption value of redeemable noncontrolling interest and other (0.9)   (0.9)           (0.9)    
Net income allocated to redeemable noncontrolling interests (2.0)                   (2.0)
Dividends paid to Greif, Inc. shareholders (31.4)   (31.4)           (31.4)    
Dividends paid to noncontrolling interests and other (0.6)                   (0.6)
Dividends earned on RSU shares 0.1   0.1           0.1    
Colleague stock purchase plan (in shares)         45   (45)        
Colleague stock purchase plan 2.5   2.5   $ 2.2   $ 0.3        
Long-term incentive shares issued (in shares)         211   (211)        
Long-term incentive shares issued 8.4   8.4   $ 6.7   $ 1.7        
Share based compensation 1.0   1.0   $ 1.0            
Restricted stock, directors (in shares)           24   (24)      
Restricted stock, directors   1.5   1.5   $ 1.3   $ 0.2      
Ending balance (in shares) at Mar. 31, 2025         47,461            
Ending balance at Mar. 31, 2025 2,140.3   2,098.8   $ 242.6   $ (276.8)   2,481.1 (348.1) 41.5
Ending balance (in shares) at Mar. 31, 2025             29,381        
Beginning balance (in shares) at Sep. 30, 2025         47,501            
Beginning balance at Sep. 30, 2025 2,952.4   2,914.9   $ 247.3   $ (276.5)   3,194.9 (250.8) 37.5
Beginning balance (in shares) at Sep. 30, 2025             29,341        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 197.2   187.2           187.2   10.0
Other comprehensive income (loss):                      
Foreign currency translation, net of income tax benefit (expense) (5.1)   (4.6)             (4.6) (0.5)
Derivative financial instruments, net of income tax benefit (expense) (0.9)   (0.9)             (0.9)  
Minimum pension liability adjustment, net of income tax (expense) benefit 2.1   2.1             2.1  
Comprehensive income 193.3   183.8                
Current period mark to redemption value of redeemable noncontrolling interest and other (1.1)   (1.1)           (1.1)    
Net income allocated to redeemable noncontrolling interests (2.5)                   (2.5)
Dividends paid to Greif, Inc. shareholders (63.6)   (63.6)           (63.6)    
Dividends paid to noncontrolling interests and other (5.5)                   (5.5)
Dividends earned on RSU shares (0.1)   (0.1)           (0.1)    
Colleague stock purchase plan (in shares)         33   (33)        
Colleague stock purchase plan 2.4   2.4   $ 1.9   $ 0.5        
Share repurchases (in shares)         (2,153)   2,153        
Share repurchases (148.6)   (148.6)   $ 0.5   $ (149.1)        
Long-term incentive shares issued (in shares)         231   (231)        
Long-term incentive shares issued 10.8   10.8   $ 7.6   $ 3.2        
Share based compensation 2.2   2.2   $ 2.2            
Share donation (in shares)         537   (537)        
Share donation 40.0   40.0   $ 33.3   $ 6.7        
Restricted stock, directors (in shares)           19   (19)      
Restricted stock, directors   0.6   0.6   $ 0.3   $ 0.3      
Deferrals of director shares in Rabbi Trust   0.9   0.9   $ 0.9          
Ending balance (in shares) at Mar. 31, 2026         46,168            
Ending balance at Mar. 31, 2026 2,981.2   2,942.2   $ 294.0   $ (414.9)   3,317.3 (254.2) 39.0
Ending balance (in shares) at Mar. 31, 2026             30,674        
Beginning balance (in shares) at Dec. 31, 2025         45,577            
Beginning balance at Dec. 31, 2025 2,978.5   2,941.1   $ 249.3   $ (406.4)   3,337.1 (238.9) 37.4
Beginning balance (in shares) at Dec. 31, 2025             31,265        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 16.3   12.6           12.6   3.7
Other comprehensive income (loss):                      
Foreign currency translation, net of income tax benefit (expense) (17.4)   (16.9)             (16.9) (0.5)
Derivative financial instruments, net of income tax benefit (expense) (0.1)   (0.1)             (0.1)  
Minimum pension liability adjustment, net of income tax (expense) benefit 1.7   1.7             1.7  
Comprehensive income 0.5   (2.7)                
Current period mark to redemption value of redeemable noncontrolling interest and other (0.5)   (0.5)           (0.5)    
Net income allocated to redeemable noncontrolling interests (1.1)                   (1.1)
Dividends paid to Greif, Inc. shareholders (31.9)   (31.9)           (31.9)    
Dividends paid to noncontrolling interests and other (0.5)                   (0.5)
Colleague stock purchase plan (in shares)         33   (33)        
Colleague stock purchase plan 2.1   2.1   $ 1.6   $ 0.5        
Share repurchases (in shares)         (229)   229        
Share repurchases (19.2)   (19.2)   $ 0.0   $ (19.2)        
Long-term incentive shares issued (in shares)         231   (231)        
Long-term incentive shares issued 10.8   10.8   $ 7.6   $ 3.2        
Share based compensation 1.0   1.0   $ 1.0            
Share donation (in shares)         537   (537)        
Share donation 40.0   40.0   $ 33.3   $ 6.7        
Restricted stock, directors (in shares)           19   (19)      
Restricted stock, directors   0.6   0.6   $ 0.3   $ 0.3      
Deferrals of director shares in Rabbi Trust   $ 0.9   $ 0.9   $ 0.9          
Ending balance (in shares) at Mar. 31, 2026         46,168            
Ending balance at Mar. 31, 2026 $ 2,981.2   $ 2,942.2   $ 294.0   $ (414.9)   $ 3,317.3 $ (254.2) $ 39.0
Ending balance (in shares) at Mar. 31, 2026             30,674